Esperion (ESPR) Data Has Something for Bulls and Bears - Stifel

October 13, 2016 11:24 AM EDT
Get Alerts ESPR Hot Sheet
Price: $11.12 --0%

Rating Summary:
    6 Buy, 5 Hold, 1 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 1 | Down: 0 | New: 0
Trade ESPR Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with's Ratings Insider Elite. Get your Free Trial here.

Stifel analyst Thomas Shrader weighed in on Esperion Therapeutics (NASDAQ: ESPR) after the company released data from the 035 study to test ETC-1002 on top of low dose statins. He said the complex will likely leave both bulls and bears happy. He also used the updated as chance to lower his price target to $30 from $64. He maintained a Buy rating.

Shrader commented, "The data were overall quite positive with benign safety profile and a 22% lowering of LDL-C relative to placebo. On a down side, the 22% included a somewhat unexpected 9% increase in the placebo group and the equivalence in plasma was based on FDA guidance that this “equivalence” is FDA-speak and implies an increase of less than 25%. Finally, the timeline for what we viewed as the major derisking event in the stock (the 900 patient 040 trial now 1950 patients) has been pushed out. All in all, if you love this stock due to a reasonable chance at a huge market, or hate this stock due to a feeling like every result seems more complex than it needs to be, there was likely nothing in today’s release to change your mind. Based on the delays implied in today’s news (albeit with improved clarity) and some R&D increases to cover the upsized trials we are lowering our target price from $64 to $30. The next major catalyst for Esperion is likely the PCSK9 CVOT readouts over the next six months."

For an analyst ratings summary and ratings history on Esperion Therapeutics click here. For more ratings news on Esperion Therapeutics click here.

Shares of Esperion Therapeutics closed at $12.32 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change, FDA

Related Entities


Add Your Comment